Compare OZ & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | OZ | SGMT |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.2M | 169.4M |
| IPO Year | 2020 | 2021 |
| Metric | OZ | SGMT |
|---|---|---|
| Price | $47.26 | $7.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $26.13 |
| AVG Volume (30 Days) | 5.0K | ★ 886.5K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,187,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 243.44 | N/A |
| 52 Week Low | $47.26 | $3.44 |
| 52 Week High | $69.00 | $11.41 |
| Indicator | OZ | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 54.11 |
| Support Level | N/A | $7.09 |
| Resistance Level | $51.50 | $7.86 |
| Average True Range (ATR) | 0.70 | 0.41 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 23.94 | 57.43 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.